Skip to main content
Wolfson Institute of Population Health

Caitlin Fierheller, PhD


Postdoctoral Research Fellow in Women’s Precision Prevention



I joined the Women’s Precision Prevention (WPP) team with Prof Ranjit Manchanda as a postdoctoral research associate in February 2023. I am currently working across clinical trials in the WPP team which focus on population-based genetic testing, targeted screening, cancer prevention (including surgical) and health economics. I am a co-investigator on the PROTECT-C (Population based germline testing for early detection and prevention of cancer) and DETECT-2 (Direct to patient testing at cancer diagnosis for precision prevention-2). I also work on the Jewish Hereditary Cancer Review, PRESCORES (Preventing Endometrial Cancers: Comparing Risk-Reducing Strategies), PROTECTOR (Prevention ovarian cancer through early excision of tubes and late ovarian removal), and other studies.

I completed my PhD in Human Genetics at McGill University, Montreal, Canada in 2023. My research focused on the molecular genetics of germline potentially pathogenic variants in DNA repair pathway genes in familial ovarian cancer. I obtained my BSc in 2016 in Genetics and Biochemistry from Western University, London, Canada.


Research Interests:

Cancer prevention

Cancer genetics

Population-based genetic testing


  • Wei X, Sun L, Slade E et al. (2024). Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer. nameOfConference

  • Wei X, Sun L, Slade E et al. (2023). EE675 Cost-Effectiveness Analysis of Cancer Susceptibility Gene-Specific Prevention and Surveillance Strategies for Ovarian and Breast Cancer. nameOfConference

  • Sobocan M, Chandrasekaran D, Sideris M et al. (2024). Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study. nameOfConference

  • Alenezi WM, Fierheller CT, Serruya C et al. (publicationYear). Genetic analyses of DNA repair pathway associated genes implicate new candidate cancer predisposing genes in ancestrally defined ovarian cancer cases. nameOfConference

    QMRO: qmroHref
  • Fierheller CT, Alenezi WM, Serruya C et al. (publicationYear). Molecular Genetic Characteristics of FANCI, a Proposed New Ovarian Cancer Predisposing Gene. nameOfConference

    QMRO: qmroHref
  • Alenezi WM, Milano L, Fierheller CT et al. (publicationYear). The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population. nameOfConference

    QMRO: qmroHref
  • Alenezi WM, Fierheller CT, Revil T et al. (publicationYear). Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants. nameOfConference

    QMRO: qmroHref
  • Fierheller CT, Guitton-Sert L, Alenezi WM et al. (2021). A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene. nameOfConference

    QMRO: qmroHref
  • Fierheller CT, Alenezi WM, Tonin PN (publicationYear). The Genetic Analyses of French Canadians of Quebec Facilitate the Characterization of New Cancer Predisposing Genes Implicated in Hereditary Breast and/or Ovarian Cancer Syndrome Families. nameOfConference

    QMRO: qmroHref
  • Alenezi WM, Fierheller CT, Recio N et al. (publicationYear). Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers. nameOfConference

    QMRO: qmroHref
Back to top